Navigation Links
Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products : Government and Industry Increase Contaminant Testing to Increase Food Safety
Date:12/2/2008

Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science research and discovery solutions, today announced that the Chinese government and two leading food manufacturers are implementing its mass spectrometry-based technologies for food analysis as part of efforts to identify and contain the spread of melamine in the food supply.

SHANGHAI, China & CARLSBAD, Calif. (Business Wire EON) December 2, 2008 -- Melamine contamination in dairy products is getting widespread attention following recent media reports of outbreaks in China and other countries. More than 94,000 infants and young children have been treated for health issues related to tainted infant formula and other products. China is responding to this issue with a series of actions that include increased food safety testing.

Melamine is a synthetic substance generally used in making plastics and fertilizer. The nitrogen-rich molecule is sometimes illegally added to consumer and animal food products in order to increase their apparent protein content. Melamine is known to cause renal and urinary problems in humans and animals; therefore, its use in food production is universally banned.

The Chinese government and industry are taking action to protect a broad range of food products and animal feed through enhanced testing procedures that require laboratory instrumentation capable of precise identification of melamine and other contaminants.

The Chinese General Administration of Quality Supervision, Inspection and Quarantine and two dairy manufacturers – Shanxi Gucheng and Yashili Dairy Company – are leading the efforts to establish the highest standards of food safety. These organizations recently deployed five API 3200™ mass spectrometry systems, which scan, identify and measure the quantity of various food contaminants. These systems deliver
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. ITRAC on track and bridging gap between academic research and applied discovery
2. Iomai Study Shows Self-Applied Travelers Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
3. Applied Precision Announces Sale of Life Sciences Business Unit to Senior Management and Telegraph Hill Partners
4. ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal
5. Open Biosystems Open Access RNAi Program Continues to Gain Momentum Worldwide
6. Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens
7. USA-ONE Interactive Presents a Free Webinar Series Introducing Docuvation – An Online Document Management Solution
8. Leading the Way in Cosmetic Surgery Los Angeles Surgeon and Beauty Expert, Dr. Christine Petti Offers Minimally Invasive SmartLipo™ – The Smart Way to Lose Fat
9. Satellite Healthcare Will Present at the American Society of Nephrology's Renal Week – Booth 527 : November 4-9, 2008
10. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2009)...eimer,s Awareness Month, and the recently released... million people worldwide will have dementia by 20...nnovator with 16 independent living and assisted l...Wisconsin and Illinois, offers the following tips ... Neenah, Wis. (Vocus) Novem...
(Date:11/10/2009)... of Public Health researchers will present Nov. 10...h Association,s annual meeting in Philadelphia, in...onal recommendations that a physician screen chest...to the Emergency Department (ED). , Additional p...ts are highlighted below. , Disparities in emer...
(Date:11/9/2009)...ilsack, Governor Patrick, and Lieutenant Governor ...e/ -- In a groundbreaking move for antihunger work...ed for all of the state,s hospitals to take an act... ,, "With 554,000 people in Massachusetts now ...ference at UMass Memorial Health Care in Worcester...
(Date:11/9/2009)...ire-Asia-FirstCall/ -- Mindray Medical,Internation...facturer and,marketer of medical devices worldwide... results for the third quarter and nine months end...ations as of September 30, 2009, -- Third quart...ase of, 3.1% over the third quarter of 2008....
(Date:11/9/2009)...Federal Trade Commission Involvement Need to be Ad...swire-USNewswire/ -- Inclusion of a provision in t...62) allowing insurance agents to sell health polic...ive, but other issues remain to be addressed in th... Professional Insurance Agents (PIA). ,, The la...
Breaking Medicine News(10 mins):Health News:Top 10 Tips for Alzheimer's Caregivers 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 3Health News:Mindray Announces Third Quarter 2009 Financial Results 2Health News:Mindray Announces Third Quarter 2009 Financial Results 3Health News:Mindray Announces Third Quarter 2009 Financial Results 4Health News:Mindray Announces Third Quarter 2009 Financial Results 5Health News:Mindray Announces Third Quarter 2009 Financial Results 6Health News:Mindray Announces Third Quarter 2009 Financial Results 7Health News:Mindray Announces Third Quarter 2009 Financial Results 8Health News:Mindray Announces Third Quarter 2009 Financial Results 9Health News:Mindray Announces Third Quarter 2009 Financial Results 10Health News:Mindray Announces Third Quarter 2009 Financial Results 11Health News:Mindray Announces Third Quarter 2009 Financial Results 12Health News:Mindray Announces Third Quarter 2009 Financial Results 13Health News:Mindray Announces Third Quarter 2009 Financial Results 14Health News:Mindray Announces Third Quarter 2009 Financial Results 15Health News:Mindray Announces Third Quarter 2009 Financial Results 16Health News:Mindray Announces Third Quarter 2009 Financial Results 17Health News:Mindray Announces Third Quarter 2009 Financial Results 18Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 2Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 3
...ad brain tumors perform worse in school than healt...ffected and girls have a harder time than boys in...ed in the issue of Neurology. Researchers say this... survivors who are at greatest risk for school fai...
...d of watery diarrhoea while over 200 were ailing f...e floods have played havoc, officials said Saturda...s including Basta, Baliapal, Bhogarai and Jaleswar...th officials were taking care of others in their r...
...akers of painkiller OxyContin agreed to pay $600 m...criminal charge of misbranding the product , one o...in such a case. Three of its current and form...d than traditional narcotics. The three execu...
...for being extra conscious in front of the camera, ...r pins looking far from perfect . The usua...both above and below her knee, making her legs loo...I suspect she works out, which is why on her thigh...
...een Patnaik Saturday ordered police to probe into ...ate's Nayagarh district, officials said . ...ths old, were found in polythene packets at Pratap... arrest has been made so far. A group of s...
...s has claimed that Chinas desire to promote eco-to...in their infancy in the Mount Huangshan Scenic Ar...ng to National Geographic, the skyrocketing infant...pectators. The study claims that this sce...
Other Medicine News:Health News:Report Shows How Children With Brain Tumors Perform at School 2Health News:Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin 2Health News:Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin 3Health News:Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin 4Health News:Chinese Eco-tourism Causing Infanticide Among Tibetan Monkeys 2
(Date:11/9/2009)..., 2009 Arena Pharmaceuti...al results for the third quarter ended September 3...ocable to common stockholders in the third quarter...pared to a net loss allocable to common stockholde...or $0.76 per share, and a net loss allocable to co...
(Date:11/9/2009)...., Nov. 9 TessArae® LLC, a gl...cations, announces the launch of new integrated pr...ns that underlie human hereditary diseases. The c...ased resequencing with novel nucleotide sequence b...s screening for all targeted mutations in multiple...
(Date:11/9/2009).... 9 AMD LASERS just announced that...esse, has accepted the position of Medical Directo... for overseeing research and development of new so...mpliance for continuing education credits, authori...lications, and lecturing and seminar engagements. ...
Breaking Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9TessArae Delivers Lower Cost Option to Genetic Testing Market 2AMD LASERS Names Dr. James Jesse as Medical Director 2Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity 5559 1ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity 5559 2
...tion Prevention Professionals With Guidelines,and ...Professionals in Infection Control and Epidemiolog...al initiatives aimed at eliminating,healthcare-ass...um,difficile-associated disease and the three infe...rvices (CMS) have classified as preventable,occurr...
...oll, Inc., a privately-held,specialty pharmaceutic...ned,phase 2 clinical trials sponsored by its wholl...investigate CollaRx(R) GENTAMICIN TOPICAL for the,... ulcers, has commenced,dosing., CollaRx GENTAMICI...Gentamicin-Collagen Sponge formulated and manufact...
Other Medicine Technology:APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS 2APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 4
Uncuffed Nasoral Murphy
Super Safety Magill Cuffed Pediatric ET
Cuffed Nasoral Murphy
Cuffed Nasoral Murphy Curved
Medicine Products: